Montelukast, a cysteinyl leukotriene receptor 1 antagonist, also induces M2 macrophage polarization and suppresses gene expression of MMP2, MMP9, and IL-1β, which inhibits murine AAA formation (43). Here, MMP9 is linked to triple-A syndrome.